IONS
NASDAQ · Biotechnology
Ionis Pharmaceuticals Inc
$44.90
+0.46 (+1.04%)
IONS News7 articles
Ionis Tumbles 9% as Heart Drug Trial Fails to Cut Events
Ionis Pharmaceuticals lost over $870 million in market value after its heart drug pelacarsen failed a Phase 3 trial. Shares fell 9.1% in after-hours trading.
Alnylam Shares Tumble 28% After Slashing Amvuttra Revenue Forecast
Shares of Alnylam Pharmaceuticals fell 28% after the firm lowered its Amvuttra revenue outlook, erasing $10.9 billion in equity value.
Arrowhead Surges 23% on Positive Plozasiran Phase 3 Data
Arrowhead Pharmaceuticals (ARWR) shares surged 23% after Plozasiran Phase 3 data showed 79-81% median triglyceride reduction and 78% fewer pancreatitis events.
ARK Invest's SpaceX Wager Shows Paper Loss Ahead of Lockup Expiry
ARK Invest's recent SpaceX purchase is underwater by $1.09M premarket as lockup expiration looms. SpaceX is now ARKK's second-largest holding at 4.36%.
Biotech Sector Hit by $15B Loss as Vertex, Ionis Stumble
Vertex and Ionis shares slumped after setbacks, erasing $14.8B in market cap. Crinetics, BridgeBio, and Vera gained $6.1B combined.
Ionis Plunges 23% After Wainua Misses Key Goal in Heart Disease Trial
Ionis stock tumbled 23% after Wainua missed its primary endpoint in a major heart disease trial, erasing $3.2 billion in market value. The setback shifts attention to the company's TRYNGOLZA launch.
Arrowhead Sees Volatility After S&P MidCap 400 Inclusion, Goldman Eyes 2026 Pipeline
Arrowhead Pharmaceuticals shares experienced heightened trading activity and a slight decline following its transition to the S&P MidCap 400 index. Goldman Sachs reiterated a Neutral stance, highlighting pivotal 2026 clinical data and competitive pressures.